Larotaxel
Breast Neoplasms
SanofiSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 65/ 100
Competitive context
177 Active assets in the Breast Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TAMOXIFEN Eli Lilly and Company | Phase 3 | BB |
Cyclophosphamide Merck Sharp & Dohme LLC | Phase 4 | BB |
Docetaxel Universitas Airlangga | Phase 4 | BB |
Inno-206 Merck Sharp & Dohme LLC | Phase 4 | BB |
EXEMESTANE Fujian Cancer Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Larotaxel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →